Brand Name: SGONEK
Price: $10 -$510/Kilogram
Place of Origin: Shaanxi, China
Certification: ISO FDA SG COA MSDS
Grade: Food Grade, Medicine Grade
Payment Terms: T/T, Western Union, MoneyGram
| Product Name: | Alendronate sodium | Cas No.: | 121268-17-5 |
| Molecular Formula: | C 4H12NNaO7P2.3(H2O) | Purity: | 99%min |
| Brand Name: | SGONEK | Certification: | ISO FDA SG COA MSDS |
|
Prodcut name |
Alendronate sodium |
|
Synonyms |
(4-Amino-1-hydroxybutylidene) bisphosphonic acid monosodium salt; Sodium 4-amino-1-hydroxy-1-phosphonobutane-1-phosphonate; Fosamax |
|
MOQ |
1G |
|
CAS No. |
129318-43-0 |
|
Appearance |
white powder |
|
Molecular Formula |
C4H12NNaO7P2 |
|
Molecular Weight |
271.08 |
|
Assay |
99% |
|
Application |
Pharma grade or research purpose |
This product is a third-generation aminodiphosphonate bone resorption inhibitor, which has strong affinity with hydroxyapatite in bone and exerts anti-bone resorption by inhibiting the activity of osteoclasts. Its anti-bone resorption effect is 1000 times stronger than that of sodium citrate, and there is no bone mineralization inhibition. The bone mass of 96% of the spine in patients treated with this product increased, and the vertebral body distortion, height shortening, and fracture incidence (including marrow, vertebrae, and carpal bone) of women with osteoporosis after menopause were improved.
| Product: | Alendronate Sodium |
| CAS No.: | 121268-17-5 |
| Melting Points : | 245°C-257°C |
| Description: | White crystalline powder |
| Identification: |
(1)physical chemistry reaction,positive reaction (2) infrared absorption atlas in accord with the reference |
| Acidity : | 4.2 ~ 4.6 |
| Chloride : | ≤ 0.01% |
| Lose on drying: | 16.0% - 17.5% |
| Sodium dihydrogen phosphite: | ≤ 0.3% |
| Total impurity: | ≤ 0.5% |
| Single impurity: | ≤ 0.1% |
| Heavy metal: | ≤ 10ppm |
| Assay: | ≥ 99.0% |
Alendronate sodium is suitable for the treatment of osteoporosis in postmenopausal women to prevent hip and spine fractures (compression of vertebral fractures). It is also suitable for osteoporosis in men to increase bone mass.
It is the third generation bisphosphonate therapy of osteoporosis drug, as a new type of high efficient bone resorption inhibitor, can inhibit the activity of osteoclast, reduce bone resorption, and not directly to restrain activity of osteoblasts.
Medicine for the treatment of postmenopausal osteoporosis and senile osteoporosis, osteoporosis, heterotopic ossification, such as Paget, Paget disease, deformation osteitis, kidney stones, malignant hypercalcemia, etc.
